placeholder image

Broad, growing pipeline of

first-in-class therapies

Broad, growing pipeline of

first-in-class therapies

Broad, growing

pipeline of first-in-class

therapies

We aim to address common medical challenges that arise as we age, focusing first on acute diseases with high unmet need

Thematic Area
Program
Mechanism of Action
Indication
Discover—É
Lead Op
IND-Enabling
Phase 1
Phase 2
Phase 3

Muscle Aging

APJ agonist
Muscle atrophy ICU diaphragm atrophy
Ph2 planning in progress
HIF-PH inhibitor
Undisclosed
Validated through Ph1

Immune Aging

Inflammasome inhibition
CNS diseases Ocular diseases (local delivery)

Brain Aging

Discovery
APJ agonist
Undisclosed Undisclosed

Portfolio strategy

A human-first approach at the intersection of known and novel aging biology

With the high throughput and diversity of targets from our platform, we are able to address disease of aging through multiple independent and orthogonal mechanisms

placeholder image

Areas of focus

Immune aging

Muscle aging

Brain aging

As we age, our natural immune defenses remain active even when not fighting infection, leading to chronic inflammatory states that degrade tissue, interfere with organ function, and drive diseases in the brain, eye, and throughout the body.

Our immune aging program defuses pathologic inflammation, restoring youthful regulation of cytokine responses and slowing or reversing disease progression.

As they age, muscles lose mass, strength, and the ability to regenerate. In older people, the resultant frailty dramatically decreases mobility, independence, and quality of life, and hinders recovery from injury.

Our muscle aging programs pursue orthogonal mechanisms to preserve or restore muscle function, enabling patients to maintain physical function and separating the process of growing older from disability and disease.

Brain aging drives debilitating disease processes that span neurosensory loss, cognitive impairment, and neurodegeneration. All interfere with daily activities, raise the risk of social isolation, and decrease quality of life.

Our longitudinal human aging cohorts provide novel insight into early drivers of brain aging, providing opportunities to delay or prevent these highly prevalent and highly morbid disease processes and allow older people to maintain independence and continue enjoying their lives

As we age, our natural immune defenses remain active even when not fighting infection, leading to chronic inflammatory states that degrade tissue, interfere with organ function, and drive diseases in the brain, eye, and throughout the body.

Our immune aging program defuses pathologic inflammation, restoring youthful regulation of cytokine responses and slowing or reversing disease progression.

As they age, muscles lose mass, strength, and the ability to regenerate. In older people, the resultant frailty dramatically decreases mobility, independence, and quality of life, and hinders recovery from injury.

Our muscle aging programs pursue orthogonal mechanisms to preserve or restore muscle function, enabling patients to maintain physical function and separating the process of growing older from disability and disease.

Brain aging drives debilitating disease processes that span neurosensory loss, cognitive impairment, and neurodegeneration. All interfere with daily activities, raise the risk of social isolation, and decrease quality of life.

Our longitudinal human aging cohorts provide novel insight into early drivers of brain aging, providing opportunities to delay or prevent these highly prevalent and highly morbid disease processes and allow older people to maintain independence and continue enjoying their lives

placeholder image

Indication strategy

Disease-first focus with an emphasis on early de-risking

placeholder image

Broader aging indications:

  • Evidence build over time may allow drugs to be used at the population level (e.g., statins)

Disease-first focus ($B+ opportunities):

  • Treating disease by targeting key aging pathways
  • High unmet need & market opportunity
  • Clear development & regulatory paths

Program de-risking:

  • Initial indications have an efficient path to POC and commercialization
Left gradient Right gradient